PI3Kδ is implicated in various inflammatory and autoimmune diseases. For the effective treatment of chronic immunological disorders such as rheumatoid arthritis, it is essential to develop isoform selective PI3Kδ inhibitors. Structure guided optimization of an imidazo-quinolinones based pan-PI3K/m-TOR inhibitor (Dactolisib) led to the discovery of a potent and orally bioavailable PI3Kδ isoform selective inhibitor (10h), with an improved efficacy in the animal models.
Keywords: Design; Imidazo-quinolinones; Inflammatory and autoimmune diseases; PI3K inhibitors; Rheumatoid arthritis; Synthesis and biological study.
Copyright © 2019 Elsevier Ltd. All rights reserved.